Buffett's twenty-slot punch card forces selectivity, patience and conviction in a single mental model. Titan Biotech's FY25 audited numbers — debt-to-equity 0.02x, ~16.9% RoCE, 103% CFO/operating profit, 55.87% promoter holding — illustrate the discipline.